William L. Elliott
About
William L. Elliott is a scholar working on Molecular Biology, Oncology and Organic Chemistry.
According to data from OpenAlex, William L. Elliott has authored 43 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 20 papers in Oncology and 11 papers in Organic Chemistry. Recurrent topics in William L. Elliott's work include HER2/EGFR in Cancer Research (12 papers), Biochemical and Molecular Research (6 papers) and Synthesis and Characterization of Heterocyclic Compounds (5 papers). William L. Elliott is often cited by papers focused on HER2/EGFR in Cancer Research (12 papers), Biochemical and Molecular Research (6 papers) and Synthesis and Characterization of Heterocyclic Compounds (5 papers). William L. Elliott collaborates with scholars based in United States, New Zealand and Malaysia. William L. Elliott's co-authors include David W. Fry, Wilbur R. Leopold, Peter L. Toogood, Patricia J. Harvey, Paul R. Keller, Erin Trachet, Nancy Pryer, Xianxian Zheng, Mudher Albassam and H. D. Hollis Showalter and has published in prestigious journals such as The Journal of Immunology, Journal of Medicinal Chemistry and International Journal of Radiation Oncology*Biology*Physics.
In The Last Decade
William L. Elliott
42 papers receiving 2.2k citations
Hit Papers
Peers
William L. Elliott
Carolyn Discafani United States
Laurent Hennequin France
Dennis J. McNamara United States
William C. Shakespeare United States
Angela V. Toms United States
Karen Lackey United States
Krystal J. Alligood United States
Anke Baum Austria
Michele Sue‐Ann Woo United States
Giorgio Caravatti Switzerland
Citations per year, relative to William L. Elliott William L. Elliott (= 1×)
peers
Carolyn Discafani
Countries citing papers authored by William L. Elliott
Since
Specialization
Citations
This map shows the geographic impact of William L. Elliott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William L. Elliott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William L. Elliott more than expected).
Fields of papers citing papers by William L. Elliott
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by William L. Elliott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William L. Elliott. The network helps show where William L. Elliott may publish in the future.
Co-authorship network of co-authors of William L. Elliott
This figure shows the co-authorship network connecting the top 25 collaborators of William L. Elliott. A scholar is included among the top collaborators of William L. Elliott based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William L. Elliott. William L. Elliott is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Elliott, William L.. (2008). Criterion validity of a computer-based tutorial for teaching waist circumference self-measurement. Journal of Bodywork and Movement Therapies. 12(2). 133–145.
2.
Allen, Lee F., Peter F. Lenehan, Irene Eiseman, William L. Elliott, & David W. Fry. (2002). Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. Seminars in Oncology. 29(3 Suppl 11). 11–21.
3.
Schroeder, Mel C., James M. Hamby, Cleo J. C. Connolly, et al.. (2001). Soluble 2-Substituted Aminopyrido[2,3-d]pyrimidin-7-yl Ureas. Structure−Activity Relationships against Selected Tyrosine Kinases and Exploration of in Vitro and in Vivo Anticancer Activity. Journal of Medicinal Chemistry. 44(12). 1915–1926.
4.
Smaill, Jeff B., Gordon W. Rewcastle, Joseph A. Loo, et al.. (2000). Tyrosine Kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4-(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides Bearing Additional Solubilizing Functions. Journal of Medicinal Chemistry. 43(7). 1380–1397.
5.
Vincent, Patrick W., Alex Bridges, Donald J. Dykes, et al.. (2000). Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts. Cancer Chemotherapy and Pharmacology. 45(3). 231–238.
6.
Smaill, Jeff B., Gordon W. Rewcastle, Alexander J. Bridges, et al.. (2000). Tyrosine Kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4-(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides Bearing Additional Solubilizing Functions.. Journal of Medicinal Chemistry. 43(16). 3199–3199.
7.
Smaill, Jeff B., H. D. Hollis Showalter, Hairong Zhou, et al.. (2000). Tyrosine Kinase Inhibitors. 18. 6-Substituted 4-Anilinoquinazolines and 4-Anilinopyrido[3,4-d]pyrimidines as Soluble, Irreversible Inhibitors of the Epidermal Growth Factor Receptor. Journal of Medicinal Chemistry. 44(3). 429–440.
8.
Thompson, Andrew M., Cleo J. C. Connolly, James M. Hamby, et al.. (2000). 3-(3,5-Dimethoxyphenyl)-1,6-naphthyridine-2,7-diamines and Related 2-Urea Derivatives Are Potent and Selective Inhibitors of the FGF Receptor-1 Tyrosine Kinase. Journal of Medicinal Chemistry. 43(22). 4200–4211.
9.
Elliott, William L., et al.. (1996). Enhanced therapeutic effect of amsalog (CI-921) in combination with cisplatin in vitro and in vivo. Oncology Reports. 3(6). 1153–9.
10.
Kunkel, Mark W., Kenneth E. Hook, Sally Przybranowski, et al.. (1995). Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice. Investigational New Drugs. 13(4). 295–302.
11.
Hoeschele, James D., H. D. Hollis Showalter, Alan J. Kraker, et al.. (1994). Synthesis, Structural Characterization, and Antitumor Properties of a Novel Class of Large-Ring Platinum(II) Chelate Complexes Incorporating the cis-1,4-Diaminocyclohexane Ligand in a Unique Locked Boat Conformation. Journal of Medicinal Chemistry. 37(17). 2630–2636.
12.
Cole, Soren, Ian J. Stratford, E.M. Fielden, et al.. (1992). Dual function nitroimidazoles less toxic than RSU 1069: selection of candidate drugs for clinical trial (RB 6145 and/or PD 130908). International Journal of Radiation Oncology*Biology*Physics. 22(3). 545–548.
13.
Keller, C., William L. Elliott, & Richard N. Hubbell. (1992). Endotracheal Tube Safety During Electrodissection Tonsillectomy. Archives of Otolaryngology - Head and Neck Surgery. 118(6). 643–645.
14.
Kraker, Alan J., James D. Hoeschele, William L. Elliott, et al.. (1992). Anticancer activity in murine and human tumor cell lines of bis(platinum) complexes incorporating straight-chain aliphatic diamine linker groups. Journal of Medicinal Chemistry. 35(24). 4526–4532.
15.
Sebolt–Leopold, Judith S., William L. Elliott, Thomas G. Heffner, et al.. (1992). Pharmacologic/pharmacokinetic evaluation of emesis induced by analogs of RSU 1069 and its control by antiemetic agents. International Journal of Radiation Oncology*Biology*Physics. 22(3). 549–551.
16.
Kraker, Alan J., Charles Watson Moore, Billy Roberts, Wilbur R. Leopold, & William L. Elliott. (1991). Preclinical antitumor activity of CI-973,[SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)] (2 methyl-1,4-butane-diamine-N,N′)platinum. Investigational New Drugs. 9(1). 1–8.
17.
Lui, May S., et al.. (1990). Oncolytic activity and mechanism of action of a novell-cystine derivative,l-cystine, ethyl ester,S-(N-methylcarbamate) monohydrochloride. Cancer Chemotherapy and Pharmacology. 26(2). 88–92.
18.
Elliott, William L., et al.. (1989). Testing for cell surface forms of class II major histocompatibility complex antigens and Ii by radioiodination, biotinylation, and membrane immunofluorescence. American Journal of Hematology. 30(1). 4–13.
19.
Thomas, Lawrence J., Quoc Viet Hung Nguyen, William L. Elliott, & Robert E. Humphreys. (1988). Proteolytic cleavage of Ii to p25.. The Journal of Immunology. 140(8). 2670–2674.
20.
Elliott, William L., Kim E. Creek, Susan L. Deutscher, et al.. (1984). Early biochemical alterations induced by 2-acetylaminofluorene in rat liver. International Journal of Biochemistry. 16(9). 947–956.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Carolyn Discafani Breakdown of academic impact, for papers by Laurent Hennequin Breakdown of academic impact, for papers by Dennis J. McNamara Breakdown of academic impact, for papers by William C. Shakespeare Breakdown of academic impact, for papers by Angela V. Toms Breakdown of academic impact, for papers by Karen Lackey Breakdown of academic impact, for papers by Krystal J. Alligood Breakdown of academic impact, for papers by Anke Baum Breakdown of academic impact, for papers by Michele Sue‐Ann Woo Breakdown of academic impact, for papers by Giorgio Caravatti